Shire Biochem Acquires Canadian Product Rights

On July 22, 2003, Quebec-based Shire BioChem, a subsidiary of Shire Pharmaceuticals Group plc, acquired the Canadian rights to five products from Mississauga, Onario-based DRAXIS Health Inc. for $13.5 million in cash, plus additional contingent milestone payments of $4 million on future product sales over several years.

Shire BioChem was represented in-house by Shona McDiarmid, vice-president, global intellectual property; Paul Pinsonnault, senior legal counsel; and Suzie Guillemette, legal counsel (corporate commercial); and assisted by Fraser Milner Casgrain LLP with a team that included Michael Beairsto, David Ujimoto and Andrea Feltham (corporate and technology).

DRAXIS Health was represented in-house by Douglas Parker, general counsel and secretary; assisted by David Woollcombe and Andrew Armstrong (corporate and securities) of McCarthy Tétrault LLP, and by Conor McCourt (intellectual property) of Torys LLP.

Lawyer(s)

David J. Ujimoto David E. Woollcombe Michael G. Beairsto Conor D.M. McCourt